CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 140 enrolled
Drug / intervention
Tirofibandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03114995
NCT03114995Phase 4Completed
CompareCT.gov

Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Seoul National University Bundang Hospital·interventional·Posted Apr 14, 2017·Updated Jul 17, 2018

In Brief

A Phase 4 clinical trial evaluating Tirofiban for Non-ST Elevation Myocardial Infarction. Completed, enrolled 140 participants.

Detailed Summary

Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-ST Elevation Myocardial Infarction
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 14, 2017
Enrollment StartFeb 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.2 years ago

Interventions

Tirofibandrug